PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

TOKYO & PRINCETON, N.J.-- (BUSINESS WIRE)--Otsuka Pharmaceutical Co, Ltd., and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted ...

ABILIFY is the first medication approved by the FDA as add-on treatment for MDD. "The approval of this new add-on treatment option is critical for adults suffering from depression who cannot find ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

“Smart pills” that can track whether or when you’ve taken your medication might be helpful for some people. Unfortunately, the first smart pill approved by the Food and Drug Administration, Abilify ...

Abilify is not a controlled substance. It’s an atypical antipsychotic drug. Abilify has some high risk side effects. It also carries boxed warnings, the most serious warnings from the Food and Drug ...

The Food and Drug Administration (FDA) issued a first-of-its-kind approval on Monday, approving the first drug in the United States with a digital ingestion tracking system. The new pill, called ...

MANHATTAN (CN) — Bristol-Myers Squibb reached a $19.5 million settlement Thursday on its off-label promotion of Abilify, an anti-psychotic that was originally designed to treat schizophrenia. Among ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...